IMPL

Impel Neuropharma Inc

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Impel Neuropharma Inc Stock Price

Vitals

Today's Low:
$3.8500
Today's High:
$4.0300
Open Price:
$3.9800
52W Low:
$3.81
52W High:
$12.56
Prev. Close:
$4.0100
Volume:
28320

Company Statistics

Market Cap.:
$0.093 billion
Book Value:
0.169
Revenue TTM:
$0.005 billion
Operating Margin TTM:
-1728%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-59.6%
Return on Equity TTM:
-369.3%

Company Profile

Impel Neuropharma Inc had its IPO on 2021-04-23 under the ticker symbol IMPL.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Impel Neuropharma Inc has a staff strength of 0 employees.

Stock update

Shares of Impel Neuropharma Inc opened at $3.98 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $3.85 - $4.03, and closed at $3.92.

This is a -2.24% slip from the previous day's closing price.

A total volume of 28,320 shares were traded at the close of the day’s session.

In the last one week, shares of Impel Neuropharma Inc have slipped by -2%.

Impel Neuropharma Inc's Key Ratios

Impel Neuropharma Inc has a market cap of $0.093 billion, indicating a price to book ratio of 24.16 and a price to sales ratio of 17.79.

In the last 12-months Impel Neuropharma Inc’s revenue was $0.005 billion with a gross profit of $0.000 billion and an EBITDA of $-0.089 billion. The EBITDA ratio measures Impel Neuropharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Impel Neuropharma Inc’s operating margin was -1728% while its return on assets stood at -59.6% with a return of equity of -369.3%.

In Q2, Impel Neuropharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Impel Neuropharma Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-4.566 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Impel Neuropharma Inc’s profitability.

Impel Neuropharma Inc stock is trading at a EV to sales ratio of 8.97 and a EV to EBITDA ratio of -0.526. Its price to sales ratio in the trailing 12-months stood at 17.79.

Impel Neuropharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Impel Neuropharma Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Impel Neuropharma Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Impel Neuropharma Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Impel Neuropharma Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Impel Neuropharma Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$3.92
52-Week High
$12.56
52-Week Low
$3.81
Analyst Target Price
$35

Impel Neuropharma Inc stock is currently trading at $3.92 per share. It touched a 52-week high of $12.56 and a 52-week low of $12.56. Analysts tracking the stock have a 12-month average target price of $35.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Impel Neuropharma Inc

The stock symbol (also called stock or share ticker) of Impel Neuropharma Inc is IMPL

The IPO of Impel Neuropharma Inc took place on 2021-04-23

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$0.53
-0
-0.36%
$0.89
-0.02
-2.07%
$3.4
0.06
+1.8%
$2.94
0.18
+6.52%
Biophytis (BPTS)
$0.59
-0.01
-1.45%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Impel NeuroPharma, Inc., an advanced-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from diseases of the central nervous system in the United States. The company is headquartered in Seattle, Washington.

Address

201 ELLIOTT AVE. W, SUITE 260, SEATTLE, WA, US